Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with ischaemic heart disease and type 2 diabetes in Swedish primary care: a cross-sectional analysis of regional primary care registry data (QregPV)
SGLT2i and GLP-1 RA were underutilised in patients with coexisting IHD and T2D. The sex disparity in SGLT2i use warrants attention, as does the substantial variation between primary healthcare centres and the challenges of implementing costly cardioprotective therapies.
Authors
- Tobias Andersson (ORCID: https://orcid.org/0000-0003-1419-8460)
- Maria Åberg (ORCID: https://orcid.org/0000-0002-0323-1061)
- Georgios Mourtzinis (ORCID: https://orcid.org/0000-0003-0147-8746)
- Margareta Hellgren
- Johan-Emil Bager
Institutions
- Sahlgrenska University Hospital (SE)
- Region Västra Götaland (SE)
- Skaraborg Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- BMJ Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-110395
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Society of Cardiology
- Svenska Läkaresällskapet